High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the other hand, subcutaneous adipose tissue might play a protective role in overall survival in cancer patients as it may provide protective nutritional reserves.50”
From Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment (2020) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationPrado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028 · cited 1×
“Enzalutamide, a next generation of androgen receptor [AR] inhibitor, has now been approved for both chemo-naı̈ve and chemo-treated mCRPC patients as it improves survival in both settings [20,21].”
BackgroundSelf-citationMourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224 · cited 1×
“Using standard operating procedures [22,23], we obtained raw data from lumbar cross-sectional areas (cm) of SMM, visceral adipose tissue (VAT) and”
MethodShen, W., Punyanitya, M., Wang, Z., Gallagher, D., St.-Onge, M.-P., Albu, J., Heymsfield, S. B., & Heshka, S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00744.2004 · Cited by 1,692 · cited 2×
“Using standard operating procedures [22,23], we obtained raw data from lumbar cross-sectional areas (cm) of SMM, visceral adipose tissue (VAT) and”
BackgroundMethodRyan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369 · cited 1×
“Abiraterone, is a CYP17 inhibitor that has been shown to improve overall survival in both chemo-treated and chemo-naive patients [17,18].”
BackgroundSelf-citationFizazi, K., Massard, C., Smith, M., Rader, M., Brown, J., Milecki, P., Shore, N., Oudard, S., Karsh, L., Carducci, M., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.001 · Cited by 142
Self-citationStorer, T. W., Miciek, R., & Travison, T. G. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.104 · Cited by 70 · cited 2×
“Epidemiological and clinical trial data provide strong evidence of reduced muscle mass and increased SAT and VAT in the presence of low testosterone levels [34–36].”
Background
Research works printed but not linked: 28
- Nelson, 2003, Prostate cancer, N Engl J Med, 349, 366, 10.1056/NEJMra021562 · DOI · Paper page
- Attard, 2015, Prostate cancer, Lancet
- Gillessen, 2015, Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015, Ann Oncol, 26, 1589, 10.1093/annonc/mdv257 · DOI · Paper page
- Armstrong, 2010, Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer, Clin Cancer Res, 16, 203, 10.1158/1078-0432.CCR-09-2514 · DOI · Paper page
- Halabi, 2014, Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer, J Clin Oncol, 32, 671, 10.1200/JCO.2013.52.3696 · DOI · Paper page
- Smith, 2012, Sarcopenia during androgen-deprivation therapy for prostate cancer, J Clin Oncol, 30, 3271, 10.1200/JCO.2011.38.8850 · DOI · Paper page
- Calle, 2003, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med, 348, 1625, 10.1056/NEJMoa021423 · DOI · Paper page
- Rodriguez, 2001, Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States, Cancer Epidemiol Biomarkers Prev, 10, 345
- Halabi, 2007, Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer, Cancer, 110, 1478, 10.1002/cncr.22932 · DOI
- Tan, 2009, Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer, Clin Cancer Res, 15, 6973, 10.1158/1078-0432.CCR-09-1525 · DOI · Paper page
- Lanic, 2014, Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immune chemotherapy, Leuk Lymphoma, 55, 817, 10.3109/10428194.2013.816421 · DOI · Paper page
- Steffens, 2011, Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?, Oncologist, 16, 1565, 10.1634/theoncologist.2011-0213 · DOI
- Naya, 2010, Influence of visceral obesity on oncologic outcome in patients with renal cell carcinoma, Urol Int, 85, 30, 10.1159/000318988 · DOI
- Ladoire, 2011, Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents, Oncologist, 16, 71, 10.1634/theoncologist.2010-0227 · DOI · Paper page
- Fizazi, 2012, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 13, 983, 10.1016/S1470-2045(12)70379-0 · DOI · Paper page
- Attard, 2012, Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer, J Clin Endocrinol Metab, 97, 507, 10.1210/jc.2011-2189 · DOI · Paper page
- Martin, 2013, Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index, J Clin Oncol, 31, 1539, 10.1200/JCO.2012.45.2722 · DOI · Paper page
- Schemper, 1996, A note on quantifying follow-up in studies of failure time, Control Clin Trials, 17, 343, 10.1016/0197-2456(96)00075-X · DOI · Paper page
- Altman, 2012, Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration, PLoS Med, 9, e1001216, 10.1371/journal.pmed.1001216 · DOI · Paper page
- Chalfin, 2014, Obesity and long-term survival after radical prostatectomy, J Urol, 192, 1100, 10.1016/j.juro.2014.04.086 · doi:10.1016/j.juro.2014.04.086
- Gonzalez, 2014, Obesity paradox in cancer: new insights provided by body composition, Am J Clin Nutr, 99, 999, 10.3945/ajcn.113.071399 · DOI · Paper page
- Kalantar-Zadeh, 2007, Risk factor paradox in wasting diseases, Curr Opin Clin Nutr Metab Care, 10, 433, 10.1097/MCO.0b013e3281a30594 · DOI · Paper page
- Camus, 2014, Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy, Eur J Haematol, 93, 9, 10.1111/ejh.12285 · DOI · Paper page
- Bing, 2008, Regulation of adipose tissue metabolism in cancer cachexia, Curr Opin Clin Nutr Metab Care, 11, 201, 10.1097/MCO.0b013e3282f948e2 · DOI
- Agustsson, 2007, Mechanism of increased lipolysis in cancer cachexia, Cancer Res, 67, 5531, 10.1158/0008-5472.CAN-06-4585 · DOI · Paper page
- Rydén, 2008, Lipolysis – not inflammation, cell death, or lipogenesis – is involved in adipose tissue loss in cancer cachexia, Cancer, 113, 1695, 10.1002/cncr.23802 · DOI · Paper page
- Hamilton, 2011, Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy, Clin Endocrinol (Oxf), 74, 377, 10.1111/j.1365-2265.2010.03942.x · DOI · Paper page
- Pezaro, 2013, Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer, Br J Cancer, 109, 325, 10.1038/bjc.2013.340 · DOI
Cited by
Cortellini, A., Bersanelli, M., Buti, S., Cannita, K., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Michiara, M., Di Marino, P., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0527-y · Cited by 413
The obesity paradox in cancer-moving beyond BMI
Strulov Shachar, S., & Williams, G. R. (2017) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0439 · Cited by 198
Hagens, E. R. C., Feenstra, M. L., van Egmond, M. A., van Laarhoven, H. W. M., Hulshof, M. C. C. M., Boshier, P. R., Low, D. E., van Berge Henegouwen, M. I., & Gisbertz, S. S. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12540 · Cited by 65
Han, Y.-H., Mun, J.-G., Jeon, H. D., Yoon, D. H., Choi, B.-M., Kee, J.-Y., & Hong, S.-H. (2020) · Nutrients · doi:10.3390/nu12103195 · Cited by 24
Systematic review and meta-analysis of lean mass and mortality: Rationale and study description
Cheung, C.-L., Lee, G. K.-Y., Au, P. C.-M., Li, G. H.-Y., Chan, M., Li, H.-L., Cheung, B. M.-Y., Wong, I. C.-K., Lee, V. H.-F., Mok, J., et al. (2021) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2021.01.001 · Cited by 18
Metadata
- Authors
- Antoun, S., Bayar, A., Ileana, E., Laplanche, A., Fizazi, K., di Palma, M., Escudier, B., Albiges, L., Massard, C., & Loriot, Y.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 51
- Issue
- 17
- Pages
- 2570-2577
- ISSN
- 0959-8049
- Cited by
- 97
- References
- 8
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. https://app.cochat.ai/papers/10.1016/j.ejca.2015.07.042
- The paper
- Antoun, S., Bayar, A., Ileana, E., Laplanche, A., Fizazi, K., di Palma, M., Escudier, B., Albiges, L., Massard, C., & Loriot, Y. (2015). High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2015.07.042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.